Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market 2019 by Company, Regions, Type and Application, Forecast to 2024

Table of Contents

1 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Overview

• 1.1 Product Overview and Scope of Non-Peptide Drugs of Angiotensin II Receptor Antagonist
• 1.2 Classification of Non-Peptide Drugs of Angiotensin II Receptor Antagonist by Types
  • 1.2.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Comparison by Types (2019-2024)
  • 1.2.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Types in 2018
  • 1.2.3 Valsartan
  • 1.2.4 Irbesartan
  • 1.2.5 Candesartan Cilexetil
  • 1.2.6 Eprosartan
  • 1.2.7 Irbesartan
  • 1.2.8 Telmisartan
  • 1.2.9 losartan
  • 1.2.10 Olmesartan Medoxomil
  • 1.2.11 Allisartan isoproxil
• 1.3 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market by Application
  • 1.3.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size and Market Share Comparison by Applications (2014-2024)
  • 1.3.2 High Blood Pressure
  • 1.3.3 Congestive Heart Failure
  • 1.3.4 Left Ventricular Hypertrophy
  • 1.3.5 Atherosclerosis
  • 1.3.6 Other
• 1.4 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market by Regions
  • 1.4.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (Million USD) Comparison by Regions (2014-2024)
  • 1.4.1 North America (USA, Canada and Mexico) Non-Peptide Drugs of Angiotensin II Receptor Antagonist Status and Prospect (2014-2024)
  • 1.4.2 Europe (Germany, France, UK, Russia and Italy) Non-Peptide Drugs of Angiotensin II Receptor Antagonist Status and Prospect (2014-2024)
  • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Non-Peptide Drugs of Angiotensin II Receptor Antagonist Status and Prospect (2014-2024)
  • 1.4.4 South America (Brazil, Argentina, Colombia) Non-Peptide Drugs of Angiotensin II Receptor Antagonist Status and Prospect (2014-2024)
  • 1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Non-Peptide Drugs of Angiotensin II Receptor Antagonist Status and Prospect (2014-2024)
• 1.5 Global Market Size of Non-Peptide Drugs of Angiotensin II Receptor Antagonist (2014-2024)

2 Manufacturers Profiles

• 2.1 Pfizer
  • 2.1.1 Business Overview
  • 2.1.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
    • 2.1.2.1 Product A
    • 2.1.2.2 Product B
  • 2.1.3 Pfizer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
• 2.2 Novartis
  • 2.2.1 Business Overview
  • 2.2.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
    • 2.2.2.1 Product A
    • 2.2.2.2 Product B
  • 2.2.3 Novartis Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
• 2.3 Merck
  • 2.3.1 Business Overview
  • 2.3.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
    • 2.3.2.1 Product A
    • 2.3.2.2 Product B
  • 2.3.3 Merck Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
• 2.4 AstraZeneca
  • 2.4.1 Business Overview
  • 2.4.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
    • 2.4.2.1 Product A
    • 2.4.2.2 Product B
  • 2.4.3 AstraZeneca Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
• 2.5 Jhonson and Johnson
  • 2.5.1 Business Overview
  • 2.5.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
    • 2.5.2.1 Product A
    • 2.5.2.2 Product B
  • 2.5.3 Jhonson and Johnson Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
• 2.6 Eli Lilly
  • 2.6.1 Business Overview
  • 2.6.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
    • 2.6.2.1 Product A
    • 2.6.2.2 Product B
  • 2.6.3 Eli Lilly Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
• 2.7 Sanofi
  • 2.7.1 Business Overview
  • 2.7.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
    • 2.7.2.1 Product A
    • 2.7.2.2 Product B
  • 2.7.3 Sanofi Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
• 2.8 Bristol-Myers Squibb
  • 2.8.1 Business Overview
  • 2.8.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
    • 2.8.2.1 Product A
    • 2.8.2.2 Product B
  • 2.8.3 Bristol-Myers Squibb Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
• 2.9 Bayer
  • 2.9.1 Business Overview
  • 2.9.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
    • 2.9.2.1 Product A
    • 2.9.2.2 Product B
  • 2.9.3 Bayer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
• 2.10 GSK
  • 2.10.1 Business Overview
  • 2.10.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
    • 2.10.2.1 Product A
    • 2.10.2.2 Product B
  • 2.10.3 GSK Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
• 2.11 Teva Pharmaceutical
  • 2.11.1 Business Overview
  • 2.11.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
    • 2.11.2.1 Product A
    • 2.11.2.2 Product B
  • 2.11.3 Teva Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
• 2.12 Shenzhen Salubris Pharmaceuticals
  • 2.12.1 Business Overview
  • 2.12.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
    • 2.12.2.1 Product A
    • 2.12.2.2 Product B
  • 2.12.3 Shenzhen Salubris Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
• 2.13 Sun Pharmaceutical
  • 2.13.1 Business Overview
  • 2.13.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
    • 2.13.2.1 Product A
    • 2.13.2.2 Product B
  • 2.13.3 Sun Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
• 2.14 Mylan
  • 2.14.1 Business Overview
  • 2.14.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
    • 2.14.2.1 Product A
    • 2.14.2.2 Product B
  • 2.14.3 Mylan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
• 2.15 Alembic Pharmaceuticals
  • 2.15.1 Business Overview
  • 2.15.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
    • 2.15.2.1 Product A
    • 2.15.2.2 Product B
  • 2.15.3 Alembic Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
• 2.16 Lupin
  • 2.16.1 Business Overview
  • 2.16.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
    • 2.16.2.1 Product A
    • 2.16.2.2 Product B
  • 2.16.3 Lupin Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
• 2.17 Aurobindo Pharma
  • 2.17.1 Business Overview
  • 2.17.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
    • 2.17.2.1 Product A
    • 2.17.2.2 Product B
  • 2.17.3 Aurobindo Pharma Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
• 2.18 Amneal Pharmaceuticals
  • 2.18.1 Business Overview
  • 2.18.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
    • 2.18.2.1 Product A
    • 2.18.2.2 Product B
  • 2.18.3 Amneal Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)
• 2.19 Boehringer Ingelheim
  • 2.19.1 Business Overview
  • 2.19.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications
    • 2.19.2.1 Product A
    • 2.19.2.2 Product B
  • 2.19.3 Boehringer Ingelheim Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)

3 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Competition, by Players

• 3.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Share by Players (2014-2019)
• 3.2 Market Concentration Rate
  • 3.2.1 Top 5 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players Market Share
  • 3.2.2 Top 10 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players Market Share
• 3.3 Market Competition Trend

4 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Regions

• 4.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Market Share by Regions
• 4.2 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
• 4.3 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
• 4.4 Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
• 4.5 South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
• 4.6 Middle East and Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)

5 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Countries

• 5.1 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Countries (2014-2019)
• 5.2 USA Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
• 5.3 Canada Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
• 5.4 Mexico Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)

6 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Countries

• 6.1 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Countries (2014-2019)
• 6.2 Germany Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
• 6.3 UK Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
• 6.4 France Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
• 6.5 Russia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
• 6.6 Italy Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)

7 Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Countries

• 7.1 Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Countries (2014-2019)
• 7.2 China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
• 7.3 Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
• 7.4 Korea Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
• 7.5 India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
• 7.6 Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)

8 South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Countries

• 8.1 South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Countries (2014-2019)
• 8.2 Brazil Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
• 8.3 Argentina Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
• 8.4 Colombia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)

9 Middle East and Africa Revenue Non-Peptide Drugs of Angiotensin II Receptor Antagonist by Countries

• 9.1 Middle East and Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Countries (2014-2019)
• 9.2 Saudi Arabia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
• 9.3 UAE Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
• 9.4 Egypt Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
• 9.5 Nigeria Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)
• 9.6 South Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)

10 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Segment by Type

• 10.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Market Share by Type (2014-2019)
• 10.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Forecast by Type (2019-2024)
• 10.3 Valsartan Revenue Growth Rate (2014-2024)
• 10.4 Irbesartan Revenue Growth Rate (2014-2024)
• 10.5 Candesartan Cilexetil Revenue Growth Rate (2014-2024)
• 10.6 Eprosartan Revenue Growth Rate (2014-2024)
• 10.7 Irbesartan Revenue Growth Rate (2014-2024)
• 10.8 Telmisartan Revenue Growth Rate (2014-2024)
• 10.9 losartan Revenue Growth Rate (2014-2024)
• 10.10 Olmesartan Medoxomil Revenue Growth Rate (2014-2024)
• 10.11 Allisartan isoproxil Revenue Growth Rate (2014-2024)

11 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Segment by Application

• 11.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Application (2014-2019)
• 11.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Forecast by Application (2019-2024)
• 11.3 High Blood Pressure Revenue Growth (2014-2019)
• 11.4 Congestive Heart Failure Revenue Growth (2014-2019)
• 11.5 Left Ventricular Hypertrophy Revenue Growth (2014-2019)
• 11.6 Atherosclerosis Revenue Growth (2014-2019)
• 11.7 Other Revenue Growth (2014-2019)

12 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Forecast (2019-2024)

• 12.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Forecast (2019-2024)
• 12.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Forecast by Regions (2019-2024)
• 12.3 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Forecast (2019-2024)
• 12.4 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Forecast (2019-2024)
• 12.5 Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Forecast (2019-2024)
• 12.6 South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Forecast (2019-2024)
• 12.7 Middle East and Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Forecast (2019-2024)

13 Research Findings and Conclusion

14 Appendix

• 14.1 Methodology